AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Carcinoma
  • Cell Proliferation
  • Dependovirus
  • Genetic Therapy
  • Ovarian Neoplasms
  • Tumor Burden

abstract

  • A single administration of AAVrh10.BevMab provides sustained and high local expression of bevacizumab in the peritoneal cavity, and significantly suppresses peritoneal carcinomatosis and increases survival in an ovarian cancer murine model.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5084530

Digital Object Identifier (DOI)

  • 10.1016/j.ygyno.2014.07.105

PubMed ID

  • 25108232

Additional Document Info

start page

  • 325

end page

  • 32

volume

  • 135

number

  • 2